Adamis Stock Jumps As Its Oral COVID-19 Drug Trial Starts Dosing

  • Adamis Pharmaceuticals Corporation ADMP has initiated dosing in the Phase 2/3 trial for Tempol, an oral antiviral product candidate, in adult patients with confirmed COVID-19 infection. 
  • The trial is designed to enroll 248 patients.
  • Related: Immunology Journal Publishes Data For Adamis' COVID-19 Candidate
  • An interim analysis by the data and safety monitoring board (DSMB) will examine safety and markers of systemic inflammation during a Stage 1 interim analysis. 
  • Based on the DSMB analysis, the Phase 3 portion of the trial designed to enroll 198 patients may begin, with a second interim analysis planned after the enrollment of 124 patients. 
  • Also Read: NIH Sees Promise in Tempol for COVID-19
  • Price Action: ADMP stock is up 2.70% at $1.14 during the market session on the last check Thursday.
Posted In: BriefsCOVID-19 CoronavirusPhase 2 TrialBiotechNewsPenny StocksHealth CareMoversTrading IdeasGeneral